Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF - Get Free Report) was the target of a large growth in short interest in September. As of September 30th, there was short interest totalling 124,900 shares, a growth of 29.8% from the September 15th total of 96,200 shares. Based on an average daily volume of 100 shares, the short-interest ratio is presently 1,249.0 days.
Newron Pharmaceuticals Price Performance
Shares of OTCMKTS NWPHF remained flat at $9.36 during mid-day trading on Friday. Newron Pharmaceuticals has a fifty-two week low of $9.10 and a fifty-two week high of $12.00. The company has a 50-day moving average of $9.29 and a 200 day moving average of $10.18.
About Newron Pharmaceuticals
(
Get Free Report)
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea.
Further Reading
Before you consider Newron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Newron Pharmaceuticals wasn't on the list.
While Newron Pharmaceuticals currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
